Nezulcitinib

Nezulcitinib (TD-0903) is an inhaled and lung-selective pan-Janus kinase (JAK) inhibitor. Nezulcitinib can be used for the research of COVID-19 associated acute lung injury and impaired oxygenation[1][2].

Product Specifications

CAS Number

[2412496-23-0]

Product Name Alternative

TD-0903

UNSPSC

12352005

Target

JAK

Type

Reference compound

Related Pathways

Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Applications

COVID-19-anti-virus

Field of Research

Infection; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/nezulcitinib.html

Solubility

10 mM in DMSO

Smiles

O=C(N1CC(C1)N(C)C)[C@@H]2CC3=C(CN2C(C)C)N=C(C4=NNC5=CC(C6=C(C=C(C=C6)O)CC)=CC=C45)N3

Molecular Formula

C30H37N7O2

Molecular Weight

527.66

References & Citations

[1]Theravance's nezulcitinib fails to meet Phase II goals in Covid-19|[2]Theravance biopharma, inc. Announces top-line results from phase 2 study of nezulcitinib in patients hospitalized with acute lung injury due to COVID-19